Janus kinase inhibitors used for chronic inflammatory conditions are only safe for certain patients, advises the EMA’s safety committee.
List view / Grid view
The European Commission has granted marketing authorisation to Stelara (ustekinumab) to treat patients aged six to 11 with moderate to severe plaque psoriasis.
The pharmaceutical industry saw some notable mergers and acquisitions in 2019; this article lists the top 10 by transaction size.
Janssen has recently received marketing authorisation from the European Commission for Stelara to treat ulcerative colitis. Dr Jaime Oliver discusses the mode of action and why the treatment is needed.
The FDA has approved the inclusion of new evidence that Cosentyx significantly slows the progression of joint structural damage..
11 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has released draft guidance recommending Apremilast for the treatment of psoriatic arthritis in adults. This appraisal was a rapid review of the NICE technology appraisal guidance published in December 2015. It focused on cost-effectiveness analyses using a patient access scheme agreement, which provides apremilast at…